KLF13 expression was downregulated in several muscle atrophy mouse models, including diabetic, DEX‐treated and cisplatin‐induced models (Figure1A,B), suggesting that KLF13 may be a convergence point for catabolic signalling across different muscle atrophy stimuli and might contribute to muscle atrophy diseases. Here, KLF13 is linked to muscle atrophy.